Wall Street analysts expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) to announce $0.28 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Harmony Biosciences’ earnings, with estimates ranging from $0.22 to $0.33. Harmony Biosciences reported earnings per share of ($0.14) in the same quarter last year, which would suggest a positive year-over-year growth rate of 300%. The company is scheduled to announce its next quarterly earnings report on Thursday, November 11th.
On average, analysts expect that Harmony Biosciences will report full year earnings of $1.04 per share for the current year, with EPS estimates ranging from $0.89 to $1.19. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.54 per share, with EPS estimates ranging from $1.95 to $3.12. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Harmony Biosciences.
Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Monday, August 9th. The company reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.18 by $0.06. Harmony Biosciences had a net margin of 9.86% and a return on equity of 66.92%. The company had revenue of $73.82 million for the quarter, compared to analyst estimates of $70.85 million.
In related news, insider Jeffrey M. Dayno sold 9,950 shares of the business’s stock in a transaction that occurred on Tuesday, August 10th. The stock was sold at an average price of $30.21, for a total transaction of $300,589.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John C. Jacobs sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 13th. The stock was sold at an average price of $35.93, for a total value of $898,250.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,159 shares of company stock valued at $1,460,926. Corporate insiders own 28.80% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC increased its stake in Harmony Biosciences by 5.4% during the first quarter. Janus Henderson Group PLC now owns 1,153,783 shares of the company’s stock worth $38,120,000 after acquiring an additional 59,334 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Harmony Biosciences by 449.0% in the 1st quarter. Nuveen Asset Management LLC now owns 55,764 shares of the company’s stock valued at $1,842,000 after acquiring an additional 45,607 shares during the period. Polaris Capital Management LLC acquired a new position in shares of Harmony Biosciences in the 2nd quarter worth approximately $872,000. Virtus ETF Advisers LLC boosted its position in shares of Harmony Biosciences by 2.8% during the 1st quarter. Virtus ETF Advisers LLC now owns 15,322 shares of the company’s stock worth $506,000 after purchasing an additional 423 shares during the period. Finally, Morgan Stanley increased its holdings in Harmony Biosciences by 205.9% in the 1st quarter. Morgan Stanley now owns 63,827 shares of the company’s stock valued at $2,109,000 after purchasing an additional 42,961 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors.
HRMY stock opened at $35.61 on Wednesday. Harmony Biosciences has a 1-year low of $25.09 and a 1-year high of $52.74. The business has a 50-day moving average price of $31.17 and a 200 day moving average price of $30.67. The company has a market capitalization of $2.03 billion and a P/E ratio of 154.83. The company has a debt-to-equity ratio of 1.55, a current ratio of 5.59 and a quick ratio of 5.46.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States.
See Also: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.